1-5 of 5
Audrey Kauffmann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Discovery of SWI/SNF Chromatin Remodeling Activity as a Novel and Targetable Dependency in Uveal Melanoma

Available to Purchase
Florencia Rago, GiNell Elliott, Ailing Li, Kathleen Sprouffske, Grainne Kerr, Aurore Desplat, Dorothee Abramowski, Julie T. Chen, Ali Farsidjani, Kay X. Xiang, Geoffrey Bushold, Yun Feng, Matthew D. Shirley, Anka Bric, Anthony Vattay, Henrik Möbitz, Katsumasa Nakajima, Christopher D. Adair, Simon Mathieu, Rukundo Ntaganda, Troy Smith, Julien P.N. Papillon, Audrey Kauffmann, David A. Ruddy, Hyo-eun C. Bhang, Deborah Castelletti, Zainab Jagani
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (10): 2186–2195.
https://doi.org/10.1158/1535-7163.MCT-19-1013
Published: 02 October 2020
View articletitled, The Discovery of SWI/SNF Chromatin Remodeling Activity as a Novel and Targetable Dependency in Uveal Melanoma
Open the PDF for The Discovery of SWI/SNF Chromatin Remodeling Activity as a Novel and Targetable Dependency in Uveal Melanoma in another window
Includes: Supplementary data
Journal Articles

FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer

Free
Andreas Weiss, Flavia Adler, Alexandra Buhles, Christelle Stamm, Robin A. Fairhurst, Michael Kiffe, Dario Sterker, Mario Centeleghe, Markus Wartmann, Jacqueline Kinyamu-Akunda, Heiko S. Schadt, Philippe Couttet, Armin Wolf, Youzhen Wang, Patrizia Barzaghi-Rinaudo, Masato Murakami, Audrey Kauffmann, Thomas Knoepfel, Nicole Buschmann, Catherine Leblanc, Robert Mah, Pascal Furet, Jutta Blank, Francesco Hofmann, William R. Sellers, Diana Graus Porta
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12): 2194–2206.
https://doi.org/10.1158/1535-7163.MCT-18-1291
Published: 02 December 2019
View articletitled, FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
Open the PDF for FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer in another window
Includes: Supplementary data
Journal Articles

Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

Free
Christine Fritsch, Alan Huang, Christian Chatenay-Rivauday, Christian Schnell, Anupama Reddy, Manway Liu, Audrey Kauffmann, Daniel Guthy, Dirk Erdmann, Alain De Pover, Pascal Furet, Hui Gao, Stephane Ferretti, Youzhen Wang, Joerg Trappe, Saskia M. Brachmann, Sauveur-Michel Maira, Christopher Wilson, Markus Boehm, Carlos Garcia-Echeverria, Patrick Chene, Marion Wiesmann, Robert Cozens, Joseph Lehar, Robert Schlegel, Giorgio Caravatti, Francesco Hofmann, William R. Sellers
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2014) 13 (5): 1117–1129.
https://doi.org/10.1158/1535-7163.MCT-13-0865
Published: 05 May 2014
View articletitled, Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
Open the PDF for Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials in another window
Includes: Supplementary data
Journal Articles

Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations

Free
Saskia M. Brachmann, Julia Kleylein-Sohn, Swann Gaulis, Audrey Kauffmann, Marcel J.J. Blommers, Malika Kazic-Legueux, Laurent Laborde, Marc Hattenberger, Fabian Stauffer, Juliane Vaxelaire, Vincent Romanet, Chrystèle Henry, Masato Murakami, Daniel Alexander Guthy, Dario Sterker, Sebastian Bergling, Christopher Wilson, Thomas Brümmendorf, Christine Fritsch, Carlos Garcia-Echeverria, William R. Sellers, Francesco Hofmann, Sauveur-Michel Maira
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (8): 1747–1757.
https://doi.org/10.1158/1535-7163.MCT-11-1021
Published: 08 August 2012
View articletitled, Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations
Open the PDF for Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations in another window
Includes: Supplementary data
Journal Articles

Abstract C193: FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a novel orally bioavailable, selective, and potent FGFR inhibitor.

Free
Diana Graus Porta, Vito Guagnano, Yao Yao, Audrey Kauffmann, Christelle Stamm, Zhi Chen, Yun Zhang, Vincent Bordas, Mickael Le Douget, Moriko Ito, Fang Li, John Monahan, Alex Gaither, Jason Borawski, Christopher J. Wilson, Kavitha Venkatesan, Thomas Bruemmendorf, Francesco Hofmann, William R. Sellers
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C193.
https://doi.org/10.1158/1535-7163.TARG-11-C193
Published: 12 November 2011
View articletitled, Abstract C193: FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a novel orally bioavailable, selective, and potent FGFR inhibitor.